A Study to Identify Barriers to Cellular Therapies for People With Plasma Cell Disorders

Memorial Sloan Kettering Cancer Center400 enrolled

Overview

This is an observational study that will include both participants with relapsed/refractory Multiple Myeloma and their doctors. The purpose of this study is to gather information about the use of hematopoietic cell transplantation/HCT and B-cell maturation antigen /BCMS targeted chimeric antigen receptor/CAR autologous T-cell therapy.

Study Type

OBSERVATIONAL

Enrollment

400

Conditions

Multiple Myeloma

Interventions

Lecture on the role of cellular therapies in relapse/refractory multiple myeloma/RRMMOTHER

Physician investigators will review a lecture on the role of cellular therapies in relapse/refractory multiple myeloma/RRMM that discusses current information in regards to available cellular therapies in RRMM and a proposed treatment algorithm.

Hospital Anxiety and Depression ScaleBEHAVIORAL

Depression and anxiety will be assessed using the Hospital Anxiety and Depression Scale (HADS), a 14-item self-rated questionnaire

Duke-UNC Functional Social Support QuestionnaireBEHAVIORAL

A 14-item, self-administered, multidimensional, functional social support questionnaire has been reduced to an 11 items to a brief and easy-to-complete two-scale, eight-item functional social support instrument.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: Patient * Diagnosis of Multiple Myeloma after January 1, 2017. * Karnofsky Performance Status \> 70% * ≥ 2 lines of prior therapy * Anticipated to start new a line of therapy for RRMM within the next 12 months * Age 18-80 years of age. * English or Spanish speaking. * Willing to provide informed consent * Willing to perform study procedures. Physician Investigator * Be a Co-Investigator * Agree to comply with study procedures Exclusion Criteria: Patient * Active CNS disease * Patients who already have a definitive plan are to be excluded

Locations (8)

Hartford Healthcare Alliance

Hartford, Connecticut, United States

NOT_YET_RECRUITING

Memorial Sloan Kettering Basking Ridge

Basking Ridge, New Jersey, United States

RECRUITING

Memorial Sloan Kettering Monmouth

Middletown, New Jersey, United States

Outcomes

Primary Outcomes

Rates of referral

To prospectively estimate the rates of referral and utilization of salvage autologous hematopoietic cell transplantation (HCT) and B cell maturation antigen (BCMA) Targeted Chimeric Antigen Receptor (CAR) autologous T cell therapies among patients with RRMM.

Time frame: Up to 76 months

Central Contacts

Heather Landau, MD

CONTACT

646-608-3740 ABMTTrials@mskcc.org

Carlyn Tan, MD

CONTACT

646-608-3778 ABMTTrials@mskcc.org

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.